CSIMarket
 
Nexalin Technology Inc   (NASDAQ: NXL)
 
Price: $5.0500 $0.26 5.428%
Day's High: $5.4899001121521 Week Perf: -18.42 %
Day's Low: $ 4.76 30 Day Perf: 1385.29 %
Volume (M): 9,712 52 Wk High: $ 7.15
Volume (M$): $ 0 52 Wk Avg: $0.77
Open: $4.76 52 Wk Low: $0.22



 Market Capitalization (Millions $) 107
 Shares Outstanding (Millions) 21
 Employees 8
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Nexalin Technology Inc is a company that specializes in the development and manufacturing of medical devices that use neurostimulation technology. Their flagship product is the Nexalin device, which is designed to deliver low-intensity transcranial electrical stimulation to help treat mental health conditions such as depression, anxiety, and insomnia. The technology works by providing electrical impulses to the brain, which have been shown to regulate brainwave patterns and improve symptoms of these conditions. Nexalin Technology Inc aims to provide safe, effective, and non-invasive alternatives to traditional treatments for mental health disorders.


   Company Address: 1776 Yorktown Street Houston 77056 TX
   Company Phone Number: 260-0222   Stock Exchange / Ticker: NASDAQ NXL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
NBIX   -1.03%    
• View Complete Report
   



Clinical Study

Strategic Leap into AI-Enhanced Healthcare Nexalin Technologys Ascension in Virtual Clinic Innovation and...

Published Mon, Dec 23 2024 3:00 PM UTC

In an epoch characterized by rapid advancements in healthcare technology, Nexalin Technology Inc. has reached a pivotal milestone. The completion of Phase 1 of its innovative Virtual Clinic AI Components signifies a remarkable leap in electronic data capture and patient monitoring. With the forthcoming integration into Phase 2, this development stands as a testament to how a...

Announcement

HOUSTON, TX, November 1, 2024 - In a significant development for its financial standing and market percepti...

Published Fri, Nov 1 2024 2:35 PM UTC

Nexalin Technology Reinstates Nasdaq Compliance with Minimum Bid Price Requirement HOUSTON, TX, November 1, 2024 - In a significant development for its financial standing and market perception, Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW), an innovative leader in neurostimulation technology, has successfully regained compliance with the Nasdaq s minimum bid price requiremen...

Stocks on the Move

title Nexalin Technology Sees Sharp Premarket Drop Amid Share Dilution Concerns

Published Sun, Jun 30 2024 11:45 AM UTC

Nexalin Tech Sees Sharp Premarket Fall Amid Dilution FearsNexalin Technology (NASDAQ: NXL) experienced a significant drop in premarket trading, with its stock falling by 40%. The decline comes after the medical device company announced a public offering of its shares, which has raised concerns among investors about share dilution.The public offering, priced at $1.75 per shar...

Clinical Study

Nexalin Technologys Breakthrough in Major Depressive Disorder Treatment Promising Clinical Study Yields Positive Res...

Published Wed, Jun 26 2024 1:01 PM UTC

Nexalin Technology, a pioneering medical firm specializing in innovative approaches to mental health disorders, has recently published the highly anticipated results of a groundbreaking clinical trial in a leading scientific journal. The study showcases the remarkable efficacy of Nexalin s DIFS (Deep Issue Frequency Specific) technology in combination with escitalopram (comm...

Stocks on the Move

Nexalin Technology Inc Challenges and Promising Outlook for a Medical Device Company

Published Tue, Jun 25 2024 3:00 PM UTC

This article sheds light on the recent developments surrounding Nexalin Technology Inc (NASDAQ: NXL), a medical device company focused on developing non-invasive therapies for various neurological disorders. By examining key events and financial indicators, we aim to present an assessment of the company s current situation, challenges, and potential opportunities. Despite s...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 491.68
Price to Sales (Expected) -
Price to Book 70.27
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.68
Working Capital Ratio 1.34
Leverage Ratio (MRQ) 0.98
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -11.51 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0.04 $
Cash 0.05 $
Book Value 0.07 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 27,144
Net Income per Employee (TTM) -1,123,608
Receivable Turnover Ratio (TTM) 4.07
Inventory Turnover Ratio (TTM) 0.17
Asset Turnover Ratio (TTM) 0.05

Profitability Ratios Current
Gross Margin (MRQ) 73.16 %
Operating Margin (MRQ) -18479.69 %
Net Margin (MRQ) -18412.71 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Nexalin Technology Inc's Segments
UNITED STATES    225 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.